Irinotecan sucrosofate - Ipsen

Drug Profile

Irinotecan sucrosofate - Ipsen

Alternative Names: Irinotecan liposome injection - Merrimack; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator HERMES BioSciences
  • Developer Medica Scientia Innovation Research; Merrimack Pharmaceuticals; PharmaEngine; Shire; University of California at San Francisco
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Breast cancer; Colorectal cancer; Gastric cancer
  • Phase I Glioma; Solid tumours
  • Phase Unknown Cholangiocarcinoma; Gallbladder cancer

Most Recent Events

  • 06 Apr 2017 Merrimack Pharmaceuticals, Rhode Island Hospital and Brown University plan the phase I/II BrUOG 329 trial for Glioblastoma (Combination therapy, Second-line therapy or greater, Recurrent) in USA (NCT03119064)
  • 03 Apr 2017 Ipsen acquires irinotecan sucrosofate from Merrimack Phamaceuticals
  • 27 Mar 2017 Merrimack Pharmaceuticals plans a phase III trial for Small cell lung cancer (NCT03088813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top